Authors
Houlahan, K. E.Livingstone, J.
Fox, N. S.
Kurganovs, N.
Zhu, H.
Sietsma Penington, J.
Jung, C. H.
Yamaguchi, T. N.
Heisler, L. E.
Jovelin, R.
Costello, A. J.
Pope, B. J.
Kishan, A. U.
Corcoran, N. M.
Bristow, Robert G
Waszak, S. M.
Weischenfeldt, J.
He, H. H.
Hung, R. J.
Hovens, C. M.
Boutros, P. C.
Affiliation
Department of Human Genetics, University of California, Los Angeles, USAIssue Date
2023
Metadata
Show full item recordAbstract
Prostate cancer is one of the most heritable cancers. Hundreds of germline polymorphisms have been linked to prostate cancer diagnosis and prognosis. Polygenic risk scores can predict genetic risk of a prostate cancer diagnosis. While these scores inform on the probability of developing a tumor, it remains unknown how germline risk influences the tumor molecular evolution. We cultivated a cohort of 1,250 localized European-descent patients with germline and somatic DNA profiling. Men of European descent with higher genetic risk were diagnosed earlier, had less genomic instability, and fewer driver genes mutated. Higher genetic risk was associated with better outcome. These data imply a polygenic "two-hit" model where germline risk reduces the number of somatic alterations required for tumorigenesis. These findings support further clinical studies of PRS as inexpensive and minimally invasive adjuncts to standard risk stratification. Further studies are required to interrogate generalizability to more ancestrally and clinically diverse populations.Citation
Houlahan KE, Livingstone J, Fox NS, Kurganovs N, Zhu H, Sietsma Penington J, et al. A polygenic two-hit hypothesis for prostate cancer. Journal of the National Cancer Institute. 2023 Jan 5. PubMed PMID: 36610996. Epub 2023/01/08. eng.Journal
Journal of the National Cancer InstituteDOI
10.1093/jnci/djad001PubMed ID
36610996Additional Links
https://dx.doi.org/10.1093/jnci/djad001Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/jnci/djad001
Scopus Count
Collections
Related articles
- Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa.
- Authors: Kim MS, Naidoo D, Hazra U, Quiver MH, Chen WC, Simonti CN, Kachambwa P, Harlemon M, Agalliu I, Baichoo S, Fernandez P, Hsing AW, Jalloh M, Gueye SM, Niang L, Diop H, Ndoye M, Snyper NY, Adusei B, Mensah JE, Abrahams AOD, Biritwum R, Adjei AA, Adebiyi AO, Shittu O, Ogunbiyi O, Adebayo S, Aisuodionoe-Shadrach OI, Nwegbu MM, Ajibola HO, Oluwole OP, Jamda MA, Singh E, Pentz A, Joffe M, Darst BF, Conti DV, Haiman CA, Spies PV, van der Merwe A, Rohan TE, Jacobson J, Neugut AI, McBride J, Andrews C, Petersen LN, Rebbeck TR, Lachance J
- Issue date: 2022 Sep 13
- Somatic mutational profiles and germline polygenic risk scores in human cancer.
- Authors: Liu Y, Gusev A, Heng YJ, Alexandrov LB, Kraft P
- Issue date: 2022 Feb 11
- Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer.
- Authors: Truong H, Breen K, Nandakumar S, Sjoberg DD, Kemel Y, Mehta N, Lenis AT, Reisz PA, Carruthers J, Benfante N, Joseph V, Khurram A, Gopalan A, Fine SW, Reuter VE, Vickers AJ, Birsoy O, Liu Y, Walsh M, Latham A, Mandelker D, Stadler ZK, Pietzak E, Ehdaie B, Touijer KA, Laudone VP, Slovin SF, Autio KA, Danila DC, Rathkopf DE, Eastham JA, Chen Y, Morris MJ, Offit K, Solit DB, Scher HI, Abida W, Robson ME, Carlo MI
- Issue date: 2023 Jan
- Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: A meta-analysis within diverse populations.
- Authors: Chen F, Darst BF, Madduri RK, Rodriguez AA, Sheng X, Rentsch CT, Andrews C, Tang W, Kibel AS, Plym A, Cho K, Jalloh M, Gueye SM, Niang L, Ogunbiyi OJ, Popoola O, Adebiyi AO, Aisuodionoe-Shadrach OI, Ajibola HO, Jamda MA, Oluwole OP, Nwegbu M, Adusei B, Mante S, Darkwa-Abrahams A, Mensah JE, Adjei AA, Diop H, Lachance J, Rebbeck TR, Ambs S, Gaziano JM, Justice AC, Conti DV, Haiman CA
- Issue date: 2022 Jul 8
- A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease.
- Authors: Bakshi A, Riaz M, Orchard SG, Carr PR, Joshi AD, Cao Y, Rebello R, Nguyen-Dumont T, Southey MC, Millar JL, Gately L, Gibbs P, Ford LG, Parnes HL, Chan AT, McNeil JJ, Lacaze P
- Issue date: 2021 Nov 19